Cited by 293SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin

Open access

Hasan, Anwarul, Paray, Bilal Ahamad, Hussain, Arif, Qadir, Fikry Ali, Attar, Farnoosh, Aziz, Falah Mohammad, Sharifi, Majid, Derakhshankhah, Hossein, Rasti, Behnam, Mehrabi, Masoumeh, Shahpasand, Koorosh, Saboury, Ali Akbar, Falahati, Mojtaba·2021·Journal of Biomolecular Structure and Dynamics

DOI 10.1080/07391102.2020.1754293PMC PMC7189411

Open this paper in CoChat — free account

Abstract

The widespread antigenic changes lead to the emergence of a new type of coronavirus (CoV) called as severe acute respiratory syndrome (SARS)-CoV-2 that is immunologically different from the previous circulating species. Angiotensin-converting enzyme-2 (ACE-2) is one of the most important receptors on the cell membrane of the host cells (HCs) which its interaction with spike protein (SP) with a furin-cleavage site results in the SARS-CoV-2 invasion. Hence, in this review, we presented an overview on the interaction of ACE-2 and furin with SP. As several kinds of CoVs, from various genera, have at their S1/S2 binding site a preserved site, we further surveyed the role of furin cleavage site (FCS) on the life cycle of the CoV. Furthermore, we discussed that the small molecular inhibitors can limit the interaction of ACE-2 and furin with SP and can be used as potential therapeutic platforms to combat the spreading CoV epidemic. Finally, some ongoing challenges and future prospects for the development of potential drugs to promote targeting specific activities of the CoV were reviewed. In conclusion, this review may pave the way for providing useful information about different compounds involved in improving the effectiveness of CoV vaccine or drugs with minimum toxicity against human health.Communicated by Ramaswamy H. Sarma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/07391102.2020.1754293

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105924 · Cited by 6,068
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
The reproductive number of COVID-19 is higher compared to SARS coronavirus
Liu, Y., Gayle, A. A., Wilder‐Smith, A., & Rocklöv, J. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa021 · Cited by 3,243
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,947
Structure, Function, and Evolution of Coronavirus Spike Proteins
Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684

Show all 84 references

Research works printed but not linked: 3

Kong R., 2020, arXiv Preprint arXiv:2003.00163, 1, 1 · arXiv
Letko M. C., 2020, bioRxiv, 1, 1
Xi J., 2020, medRxiv, 1, 1

Sorted by citations

Items 201–290 of 290

The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern
Guest, P. C., Kesharwani, P., Butler, A. E., & Sahebkar, A. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-28012-2_1 · Cited by 8
COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2
Deshmukh, R., Harwansh, R. K., Garg, A., Mishra, S., Agrawal, R., & Jangde, R. (2024) · Current Genomics · doi:10.2174/0113892029291098240129113500 · Cited by 9
Smart polymeric eye gear: A possible preventive measure against ocular transmission of COVID-19
Sahu, D. K., Pradhan, D., Naik, P. K., Kar, B., Ghosh, G., & Rath, G. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110288 · Cited by 8
SARS-CoV-2: cómo es, cómo actúa y cómo se expresa en la imagen
Fernández-Pérez, G. C., Miranda, M. O., Fernández‐Rodríguez, P., Casares, M. V., de la Calle, M. C., López, Á. F., Blanco, M. D., & Cuchat, J. M. O. (2020) · Radiología · doi:10.1016/j.rx.2020.10.006 · Cited by 8
Sequence Analysis, Structure Prediction of Receptor Proteins and In Silico Study of Potential Inhibitors for Management of Life Threatening COVID-19
Chatterjee, A., Basak, H. K., Saha, S., Ghosh, J., Paswan, U., Karmakar, S., & Pal, A. (2021) · Letters in Drug Design & Discovery · doi:10.2174/1570180818666210804141613 · Cited by 8
SARS-CoV-2: what it is, how it acts, and how it manifests in imaging studies
Fernández-Pérez, G. C., Miranda, M. O., Fernández‐Rodríguez, P., Casares, M. V., de la Calle, M. C., López, Á. F., Blanco, M. D., & Cuchat, J. M. O. (2021) · Radiología (English Edition) · doi:10.1016/j.rxeng.2020.10.006 · Cited by 7
Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial
Pantazopoulos, I. N., Chalkias, A. F., Mavrovounis, G., Dimeas, I. E., Sinis, S. I., Miziou, A., Rouka, E. C., Poulas, K. A., & Gourgoulianis, K. I. (2022) · Canadian Respiratory Journal · doi:10.1155/2022/8794127 · Cited by 7
Detection of SARS-CoV-2 and Its Related Factors on the Mucosal Epithelium of the Tongue
Tamiya, J., Sakaguchi, W., Nakagawa, K., Yamamoto, T., Saruta, J., Kubota, N., Kawata, A., Hasegawa, I., Hamada, N., & Tsukinoki, K. (2023) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.22-00089 · Cited by 7
Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin
Wzorek, J., Bednarek, R., Watała, C. W., & Boncler, M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638257 · Cited by 7
SARS-CoV-2 D614 and G614 spike variants impair neuronal synapses and exhibit differential fusion abilityPreprint
Chen, C.-Y., Chou, Y., & Hsueh, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.03.409763 · Cited by 8
An overview of potential therapeutic agents to treat COVID-19
Dong, X., Tian, Z., Shen, C., & Zhao, C. (2020) · BioScience Trends · doi:10.5582/bst.2020.03345 · Cited by 6
Development of a SARS‐CoV‐2 neutralization assay based on a pseudotyped virus using a HIV system
Liang, Z., Tong, J., Wu, X., Liu, S., Wu, J., Yu, Y., Zhang, L., Zhao, C., Lu, Q., Nie, J., et al. (2024) · MedComm · doi:10.1002/mco2.517 · Cited by 6
Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective
Chakraborty, A., Ghosh, R., Mohapatra, S. S., Barik, S., Biswas, A., & Chowdhuri, S. (2024) · Gene · doi:10.1016/j.gene.2024.148553 · Cited by 7
Delta variant: Partially sensitive to vaccination, but still worth global attention
Zhang, M., He, Y.-C., & Jie, Z. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0026 · Cited by 6
Emerging Treatment Approaches for COVID-19 Infection: A Critical Review
Bharadwaj, A., Kaur, R., & Gupta, S. K. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230417112543 · Cited by 5
From genomes to molecular dynamics – A bottom up approach in extrication of SARS CoV-2 main protease inhibitors
Aishwarya, S., Gunasekaran, K., Jansi, R. S., & Sangeetha, G. (2021) · Computational Toxicology · doi:10.1016/j.comtox.2021.100156 · Cited by 5
Molecular Docking Analysis of the Phytochemicals from Tinospora Cordifolia as Potential Inhibitor Against Multi Targeted SARS-CoV-2 & Cytokine Storm
Panigrahi, D. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500277 · Cited by 5
Application of Nanotechnology in COVID-19 Infection: Findings and Limitations
Shehu, I. A., Musa, M. K., Datta, A., & Verma, A. (2022) · Journal of Nanotheranostics · doi:10.3390/jnt3040014 · Cited by 5
The main protease of SARS-CoV-2 as therapeutic target to development specific drugs to treat COVID-19
da Silva-López, R. E. (2020) · Journal of Applied Biotechnology & Bioengineering · doi:10.15406/jabb.2020.07.00232 · Cited by 4
Virus-CKB 2.0: Viral-Associated Disease-Specific Chemogenomics Knowledgebase
Hao, Y., Chen, M., Othman, Y., Xie, X., & Feng, Z. (2022) · ACS Omega · doi:10.1021/acsomega.2c04258 · Cited by 4
Improving Antimicrobial Stewardship in Human Health Using Probiotics and Their Derivatives
Nyathi, N., Ndhlovu, D., Rabvukwa, E., & Ndudzo, A. (2024) · Pharmaceutical science. · doi:10.5772/intechopen.112497 · Cited by 4
Pre-pandemic artificial MERS analog of polyfunctional SARS-CoV-2 S1/S2 furin cleavage site domain is unique among spike proteins of genus Betacoronavirus
Lisewski, A. M. (2024) · BMC Genomic Data · doi:10.1186/s12863-024-01290-2 · Cited by 4
Computational Repurposing of Relatively Large Drugs for the Receptor Binding Domain of SARS‐CoV‐2 Spike Protein
Almatarneh, M. H., Alqaisi, A. M., Al‐Shanti, A. N., Abu‐Saleh, A. A. A., Al‐Sheraideh, M. S., Zhao, Y., & Uddin, K. M. (2025) · ChemistrySelect · doi:10.1002/slct.202502784 · Cited by 4
Antiviral drugs prioritization for COVID-19 management based on rational selection
Joshi, R. S., Giri, A. P., Kulkarni, M. J., Gupta, M. C., Verma, S., Chaudhry, D., Deshmukh, N., & Chugh, A. (2021) · Current Science · doi:10.18520/cs/v120/i9/1464-1470 · Cited by 4
Internalization-related host factors of common respiratory viruses
Lv, Q., Xie, Z., & Xu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1724561 · Cited by 3
Spike protein-related proteinopathies: A focus on the neurological side of spikeopathies
Posa, A. (2025) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2025.152662 · Cited by 3
The Role of Inflammasomes in COVID-19: Potential Therapeutic Targets
Sun, C., Zhao, H., Han, Y., Wang, Y., & Sun, X. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0061 · Cited by 3
Potential antiviral peptides against the nucleoprotein of SARS-CoV-2
Mahdi, I., Yeasmin, H., Hossain, I., Badhan, R. M., Ali, M., Kaium, M. A., Islam, R., Sufian, M. A., & Halim, M. A. (2022) · Chemical Papers · doi:10.1007/s11696-022-02514-4 · Cited by 3
SARS-CoV-2 variants infectivity prediction and therapeutic peptide design using computational approaches
Abhinand, C. S., Prabhakaran, A. A., Krishnamurthy, A., Raju, R., Prasad, T. S. K., Nair, A. S., Rajasekharan, K. N., Oommen, O. V., & Sudhakaran, P. R. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2160819 · Cited by 3
Initial mean arterial blood pressure (MABP) measurement is a risk factor for mortality in hypertensive COVID-19 positive hospitalized patients
Yangchen, T., Koraishy, F. M., Xu, C. Q., Hou, W., & Rohatgi, R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283331 · Cited by 3
IN SILICO STUDY: SECONDARY METABOLITES FROM RED GINGER RHIZOME (Zingiber Officinale Var. Rubrum) AS POTENTIAL INHIBITORS OF3CLpro AND PLpro OF SARS-CoV-2
Suherman, M., & Maulidya, S. A. I. (2023) · Medical Sains Jurnal Ilmiah Kefarmasian · doi:10.37874/ms.v8i3.810 · Cited by 3
Relaxed complex scheme and molecular dynamics simulation suggests small molecule inhibitor of human TMPRSS2 for combating COVID-19
Vuai, S. A. H., Ogedjo, M. M., Onoka, I. M., Sahini, M. G., Swai, H., & Shadrack, D. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1997817 · Cited by 3
Natural products as a therapy to combat against SARS-CoV-2 virus infection
Malviya, S., Parihar, A., Parihar, D. S., & Khan, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91172-6.00017-0 · Cited by 3
From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic
Estella, Á., & Garnacho‐Montero, J. (2020) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2020.09.001 · Cited by 3
COVID-19;-The origin, genetics,and management of the infection of mothers and babies
El‐Sayyad, H. I., & Abdalhafid, Y. K. A. (2020) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2020.1843119 · Cited by 3
Molecular targets in SARS-CoV-2 infection: An update on repurposed drug candidates
Rahmani, D., Jafari, A., Kesharwani, P., & Sahebkar, A. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155589 · Cited by 4
Functionalized nanostructures and targeted delivery systems with a focus on plant-derived natural agents for COVID-19 therapy: A review and outlook
AbouAitah, K., Kim, B. S., & Łojkowski, W. (2024) · Nanotechnology Reviews · doi:10.1515/ntrev-2024-0102 · Cited by 2
Golden Pigment Curcumin: An Inspiring Antiviral Molecular Model for COVID-19 Drug Design
(2020) · Gazi Medical Journal · doi:10.12996/gmj.2020.115 · Cited by 2
Phyto-Compounds from a Rather Poisonous Plant, Strychnos nuxvomica, Show High Potency Against SARS-CoV-2 RNA-Dependent RNA Polymerase
Balkrishna, A., Pokhrel, S., & Varshney, A. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666210218113409 · Cited by 2
Virtual screening of bioactive anti-SARS-CoV natural products and identification of 3β,12-diacetoxyabieta-6,8,11,13-tetraene as a potential inhibitor of SARS-CoV-2 virus and its infection related pathways by MD simulation and network pharmacology
Huq, A. M., Roney, M., Imran, S., Khan, S. U., Uddin, M. N., Htar, T. T., Baig, A. A., Bhuiyan, M. A., Zakaria, Z. A., Aluwi, M. F. F. M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2176926 · Cited by 2
Coronavirus disease 2019 and its potential animal reservoirs: A review
Islam, M. S., Hasib, F. M. Y., Nath, C., Ara, J. E., Nu, M. S., Fazal, M. A., & Chowdhury, S. (2021) · International Journal of One Health · doi:10.14202/ijoh.2021.171-181 · Cited by 2
A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
Karbasforooshan, H., Salari, S., & Hosseinjani, H. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220218115617 · Cited by 2
Unlocking the Potential of Ghost Probiotics in Combating Antimicrobial Resistance
Ndudzo, A., Ndlovu, S., Nyathi, N., & Sibanda-Makuvise, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104126 · Cited by 3
Role of Indian Medicinal Plants for Immunity Booster Against SARS-CoV-2 Infection: An Updated Review
Verma, K., Mishra, Y., Kapoor, N., & Yadav, N. (2023) · Current Nutrition & Food Science · doi:10.2174/1573401319666230718112058 · Cited by 2
Is The SARS-CoV2 Evolved in Human Being: A prospective Genetic Analysis
Dimonte, S., Jalal, P. J., Ahmad, H. A., Karim, S. B., Soor, T. A. H., Ali, S. I., Babakir‐Mina, M., & Greco, F. (2020) · Kurdistan Journal of Applied Research · doi:10.24017/science.2020.ichms2020.19 · Cited by 2
A Comprehensive Review and Perspective of Herbal Medicines in the Treatment of COVID-19
Moin, A., Meenakshi, S. S., Rizvi, S. M. D., Nandini, N., Hussain, T., Hussain, A., Meghana, G. S., Manohar, M., Paranthaman, S., & Gowda, D. V. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i26a31473 · Cited by 2
Self-citation
Investigation of the Interaction of Sorafenib with Alpha-Lactalbumin: Spectroscopic and Molecular Modeling
Bagheri, F., & Fatemi, M. H. (2021) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162021040038 · Cited by 2
Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19
Suzy, S., Hoste, L., & Vanham, G. (2022) · OTORHINOLARYNGOLOGY · doi:10.37219/2528-8253-2022-1-78 · Cited by 2
Anti Hepatitis C virus drugs show potential drug repositioning for SARS CoV-2 main protease: an in silico studyPreprint
Anandamurthy, A., Varughese, R. E., Sivaraj, S., & Gayathri, D. (2020) · doi:10.21203/rs.3.rs-26489/v1 · Cited by 2
Discovery of Natural Phenol Catechin as a Multitargeted Agent Against SARS-CoV-2 For the Plausible Therapy of COVID-19Preprint
Mishra, C. B., Pandey, P., Sharma, R. D., Mongre, R. K., Lynn, A. M., Prasad, R., Jeon, R., & Prakash, A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12752402 · Cited by 2
Investigation of Neolamarckia cadamba phytoconstituents against SARS-CoV-2 3CL Pro: An In-Silico Approach
Arora, S., Tirpude, K., Rushiya, P., Sapkal, N. P., Yende, S. R., Ittadwar, A., & Shah, S. (2023) · Orbital - The Electronic Journal of Chemistry · doi:10.17807/orbital.v15i1.17592 · Cited by 1
Unveiling the Multifaceted Antiviral Properties of Cordyceps
Verma, A. K., Dutta, D., Das, J., & Singh, N. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-6345-0_10 · Cited by 1
Yeast-two-hybrid based high-throughput screening to discover SARS-CoV-2 fusion inhibitors by targeting the HR1/HR2 interaction
Zhang, J., Li, D., Zhou, W., Liu, C., Wang, P., You, B., Su, B., Guo, K., Shi, W., Yung, T. M. T., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.029 · Cited by 1
Integrating host-pathogen interactions with AI, cheminformatics and network pharmacology for peptide-based dual inhibitors against SARS-CoV-2
Al-Khafaji, K., Shuwaili, M., & Salman, H. A. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00602-5 · Cited by 1
The expanding role of Furin in human Disease: A comprehensive review
Li, X., Liu, C., & Hu, H. (2025) · Gene · doi:10.1016/j.gene.2025.149969 · Cited by 1
Brain inflammatory thrombogenic vasculopathy related with SARS-CoV-2 infection
Porta-Etessam, J., Yus, M., García, N. G., Valcarcel, A., Cuchillo, J. B., & Pérez‐Somarriba, J. (2020) · Neurología · doi:10.1016/j.nrl.2020.07.012 · Cited by 1
Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19
Khodajou-Masouleh, H., Shahangian, S. S., & Rasti, B. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1928686 · Cited by 1
Self-citation
Virtual screening as therapeutic strategy of COVID-19 targeting angiotensin-converting enzyme 2
Sharifinia, Z., Asadi, S., Irani, M., & Allahverdi, A. (2021) · Frontiers in Molecular Immunology · doi:10.25082/fmi.2021.01.002 · Cited by 1
In Silico Identification of Potential Inhibitors of Substituted Quinazolin-4-One against Main Protease and Spike Glycoprotein of Sars Cov-2
Kavitha, K., Srinivasan, N., Suresh, R., & Surapaneni, K. M. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00407 · Cited by 1
A computational analysis of molecular evolution for virulence genes of zoonotic novel coronavirus (COVID-19)
Kumari, P., & Poddar, R. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107532 · Cited by 1
Therapeutic Profile of Glycyrrhiza glabra: A Ray of Hope in Treating COVID-19
Shehu, I. A., & DATTA, A. (2022) · Malaysian Journal of Pharmaceutical Sciences · doi:10.21315/mjps2022.20.2.12 · Cited by 1
In silico analysis of Osciallatoria sp. for SARS-CoV-2 protease inhibiting bioactive compounds
Mohideen, A. P., Shamna, K. P., & Alfaki, M. A. (2022) · Annals of Phytomedicine An International Journal · doi:10.54085/ap.2022.11.2.36 · Cited by 1
Docking of Velpatasvir to the SARS-CoV-2 Viral Spike Protein-Human ACE2 Complex: repurposing for COVID-19Preprint
Zia, A., Akhtar, S., & Khan, M. A. (2021) · Research Square · doi:10.21203/rs.3.rs-1013200/v1 · Cited by 1
Breaking the Rules of Respiratory Diseases: Reviewing the Current Perspectives Regarding Thrombotic Conditions Associated with SARS-CoV-2 Infection
King, B. (2020) · Neurology & Neurotherapy Open Access Journal · doi:10.23880/nnoaj-16000151 · Cited by 1
Impact of Natural Products on Developing New Treatments for Corona Virus Disease (COVID-19): Review
Saddiq, A. A., Danial, E. N., & Saraf, I. A. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i28b31543
Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review
Moharir, K. S., Arora, S., Yende, S. R., Lohiya, G. K., & Shah, S. (2021) · The Open COVID Journal · doi:10.2174/2666958702101010065
The Effectiveness Of Education And Workshop For Making Natural Disinfectants With Antiseptics From Water Steam Of Piper betle Leaves In The Production Warehouse Telaga Bidadari Village
Ahsana, D., & Muthmainnah, M. (2021)
Potential of propolis against SARS CoV-2 coronavirus infection
Kolaylı, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85400-9.00006-x
Rationale Based Selection and Prioritization of Antiviral Drugs for COVID-19 ManagementPreprint
Joshi, R. S., Giri, A. P., Kulkarni, M. J., Gupta, M., Verma, S., Chaudhary, D., Deshmukh, N. S., & Chugh, A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12429629
Review Of Covid-19 Vaccines
Musafer, H. K., Abdulrazaq, R. A., Ali, B. M., & Kaabi, S. A. G. (2021) · Journal of university of Anbar for pure science · doi:10.37652/juaps.2022.172451
Probiótico: avaliação da atividade antimicrobiana in vitro e do efeito in vivo na progressão de lesões periapicais, por meio de análise microscópica
Araújo, L. D. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.58.2020.tde-07102022-162536
Análisis in silico de la inmunogenicidad e interacción molecular de péptidos de plantas aromáticas con SARS-CoV-2
Delgado-Betancourt, A. L., Zuñiga-Lopez, M. H., & García-López, J. P. (2022) · Revista de la Asociación Colombiana de Ciencias Biológicas · doi:10.47499/revistaaccb.v1i34.264
In silico disease modeling for COVID-19
Yiannakopoulou, E. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91794-0.00012-3
Epidemiological studies of COVID-19 disease
Maryam, S., Fatima, R., Ashfaq, M., Hassan, N., Bibi, A., Syed, A., & Kamran, M. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v7ns1.14303
Stimulation of immune response in mice using the plant-produced SARS-CoV-2 S1 subunit protein linked to the fc region
Panapitakkul, C., & Phoolcharoen, W. (2022) · doi:10.58837/chula.the.2022.287
COVID-19 Pathogenesisin the oral cavity: A Review on Oral Impairments and Manifestations
Torgomyan, A., Saroyan, M., Hovhannisyan, S., Mashinyan, K., Yessayan, L., & Hakobyan, G. (2023) · SUCHASNA STOMATOLOHIYA · doi:10.33295/1992-576x-2023-1-2-8
Manifestations COVID-19 in the Oral Cavity: A Systematic Review
Torgomyan, A., Saroyan, M., Hovhannisyan, S., Mashinyan, K., Yessayan, L., & Hakobyan, G. (2023) · Microbiology & Infectious Diseases · doi:10.33425/2639-9458.1176
Pathological changes in oral epithelium and the expression of SARS-CoV-2 entry receptors, ACE2 and furin
Koren, O. G., Lusthaus, M., Tabibian‐Keissar, H., Kaplan, I., Buchner, A., Ilatov, R., Vered, M., & Zlotogorski‐Hurvitz, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300269
SARS-CoV-2 and Angiotensin-Converting Enzyme-2 Receptor Interaction Blocker– an In-Silico Approach
Khan, Z., Suleman, M., Tariq, H., Mumtaz, M., Azam, H. M. H., Hussain, N., Sarfraz, H., Baqar, Z., Munir, H., & Zulfiqar, M. (2024) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v5i03.1340
Pre-pandemic artificial MERS analog of pathogenic polyfunctional SARS-CoV-2 S1/S2 furin cleavage site domain is unique among betacoronavirusesPreprint
Lisewski, A. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4282844/v1
In silico study of polyphenol compounds from green tea (Camellia sinensis L.) as inhibitors of 3CLPRO of SARS-COV2
Junaidin, J., Maulidya, S. A. I., Budipramana, K., Ismail, F., Yuniarta, T. A., & Sylvia, D. (2023) · The Thai Journal of Pharmaceutical Sciences · doi:10.56808/3027-7922.2827
The Study of the COVID-19 Virus: A Review
Forsythe, M. L. (2024) · The Open COVID Journal · doi:10.2174/0126669587296962240521114748
General Characteristics and Properties of Organic Life
Knoflacher, M. (2024) · Springer eBooks · doi:10.1007/978-3-662-69423-7_5
Development of an in-house primer design: Nested polymerase chain reaction for coronavirus disease 2019 detection based on open reading frame 1a/b and spike
Kurniawati, S., Winarsih, S., Andarini, S., Rizky, D. R., Ardiana, R., Perdana, W. Y., & Tulle, A. (2024) · International Journal of One Health · doi:10.14202/ijoh.2024.178-182 · Cited by 1
Synergistic Integration of Multimodal Modeling Approaches for Accelerated COVID-19 Therapeutic Development
Goel, M., Gupta, K., Srivastava, I., & Gabrani, R. (2025) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-031-80189-1_15
Quantum Chemical and Metabolomic Characterization of Inhibitory Activity of Procyanidins and Flavonol Glucosides From Graptopetalum paraguayense E. Walther Against Nonstructural Proteins of SARS‐CoV‐2
Stoyanova, N., Rangelov, M. A., Todorova, N. H., Dincheva, I. N., Badjakov, I. K., Enchev, V. G., & Markova, N. V. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500259
EXPANSION STRATEGIES TO DESIGN HYBRID MOLECULES OF FDA APPROVED DRUGS AS POTENTIAL INHIBITORS OF SARS Co-V-2 MAIN PROTEASE (Mpr)
Thomas, T. V., Thakur, A., & Kumar, S. A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i2.53121
Structure-based screening of antiviral phytocompounds from the IMPPAT database against SARS-CoV-2 main protease using molecular docking, MM-GBSA, MD simulation, and DFT analysis
Vivekananthan, N., Nath, V., Marimuthu, C., Kumar, N., Rao, C. V., & Selvaraj, V. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100102
Computational screening of lichen bioactive compounds as a potential antiviral agent against SARS-CoV-2 main proteases
Preethi, S., Annadurai, Y., Arunkumar, M., Murugesh, E., Ponmurugan, P., & Piramanayagam, S. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00564-0
The relationship between the oral health status and COVID-19 and Influenza infectionsPreprint
Tonouchi, K., Sakai, H., Kajihara, R., Shimizu, S., Fukuda, H., Otagiri, H., Matsuzawa, K., & Kurita, H. (2026) · Research Square · doi:10.21203/rs.3.rs-11242603/v1

Authors: Hasan, A., Paray, B. A., Hussain, A., Qadir, F. A., Attar, F., Aziz, F. M., Sharifi, M., Derakhshankhah, H., Rasti, B., Mehrabi, M., Shahpasand, K., Saboury, A. A., & Falahati, M.
Affiliations: Qatar University (QA)
King Saud University (SA)
Manipal Academy of Higher Education, Dubai (AE)
Salahaddin University-Erbil (IQ)
Standard Research Institute (IR)
Islamic Azad University, Tehran (IR)
Kermanshah University of Medical Sciences (IR)
Islamic Azad University, Lahijan Branch (IR)
Royan Institute (IR)
University of Tehran (IR)
Corresponding author: Hasan, Anwarul
Falahati, Mojtaba
ORCID: Hasan, Anwarul
Hussain, Arif
Qadir, Fikry Ali
Sharifi, Majid
Derakhshankhah, Hossein
Rasti, Behnam
Shahpasand, Koorosh
Saboury, Ali Akbar
Falahati, Mojtaba
Venue: Journal of Biomolecular Structure and Dynamics
Publisher: Informa UK Limited
Published: 2020-04-22
Volume: 39
Issue: 8
Pages: 3025-3033
ISSN: 0739-1102 (ISSN-L)
1538-0254
DOI: 10.1080/07391102.2020.1754293
PMC: PMC7189411
OpenAlex: W3015385976
Cited by: 293
References: 84
Citations by year: 2026: 3 · 2025: 9 · 2024: 18 · 2023: 24 · 2022: 40 · 2021: 83 · 2020: 115
FWCI: 3.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Biomolecular Structure and Dynamics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Qatar University QSpace (Qatar University) (submittedVersion)
Funders: Qatar Foundation (GCC-2017-005, NPRP10-120-170-211)
Fonds National de la Recherche Luxembourg
Qatar University (GCC-2017-005)
Qatar National Research Fund (NPRP10, NPRP10-120-170-211, GCC-2017-005)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, spike protein, furin cleavage site, angiotensin-converting enzyme 2, viral entry, host cell receptors, S1/S2 cleavage, small molecule inhibitors, antiviral drug discovery, coronavirus vaccines
MeSH terms: Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Angiotensins, Humans, Furin, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks